Guardant Health, Inc. · NASDAQ:GH
Guardant Health — Technical Presentation (2022)
11 slides from Guardant Health's technical presentation, May 24, 2022
Slide 1: Multi-modal blood-based colorectal cancer screening is a viable screening option – a prospective study
Multi-modal blood-based colorectal cancer screening is a viable colorectal cancer screening option – a prospective study Paloma Peinado1,7, Enrique Sanz-Garcia1, Maria Castro-Henriques2, Teresa Curiel-Garcia3, Susana Prados4, Rafael Alvarez- Gallego1,7, Jesus Rodriguez-Pascual5,7, Marcial Garcia-Mor
Slide 2: Disclosures
Disclosures Paloma Peinado Research funding from Guardant Health. Speaking fees from Merck and Lilly. @DDWMeeting | #DDW2022
Slide 3: Background
Background • Despite the availability of multiple colorectal cancer (CRC) screening options, about one-third of 80% Na'onal Goal1,2 individuals are not up to date with CRC screening1,2 • Screening adherence rates have remained below the 80% target set forth by leading health care organizations • A b
Slide 4: Background: Blood-based CRC screening test
Background: Blood-based CRC screening test • Retrospective studies of a multimodal blood- based test in individuals with early-stage CRC have yielded promising results: • In a previously reported case-cohort study, this blood-based test demonstrated 91% CRC sensitivity at 94% specificity1 • However,
Slide 5: Methods: Clinical Cohort
Methods: Clinical Cohort • Real world, prospective, observational study of adults Age 45 – 84 years Exclusion: undergoing colonoscopy at one of four hospitals in Spain • History of any malignancy, including CRC Undergoing • Colonoscopy in last 9 years • Enrollment target: n = 600 individuals colonos
Slide 6: Cohort Demographics
Cohort Demographics At the Gme of analysis, 93% (n=557) of Indication for Colonoscopy individuals had a complete colonoscopy and a Positive Family blood sample analyzed Positive History Other 11% 1% Demographics (N = 557) FIT/FOBT Number of 6% Symptomatic % of total 49% Subjects Male 269 48.3% Biolo
Slide 7: Results: Sensitivity and Specificity
Results: Sensitivity and Specificity At 90% Specificity, CRC sensitivity was 100% 100% 100% 90% • No differences in sensitivity or specificity based on the indication for colonoscopy. CRC Stage N I 1/1 • Specificity did not differ when restricting the 50% II 3/3 analysis to only those with negative
Slide 8: Results: Sensitivity and Specificity
Results: Sensitivity and Specificity At 90% Specificity, CRC sensitivity was 100% At 95% Specificity, CRC sensitivity was 88% 100% 100% 100% 95% 90% 88% CRC Stage N CRC Stage N I 1/1 I 1/1 50% II 3/3 50% II 2/3 III 2/2 III 2/2 IV 2/2 IV 2/2 Overall 8/8 Overall 7/8 0% 0% Specificity CRC Sensitivity S
Slide 9: Strengths and Limitations
Strengths and Limitations Strengths: Limitations: • Prospective study conducted at • Given this is a real-world analysis, multiple institutions referral patterns were based on • “All-comers” population national guidance in Spain, leading to a higher proportion of individuals • First prospective eval
Slide 10: Conclusions
Conclusions: • In this real-world, prospective study of individuals eligible for colonoscopy, sensitivity and specificity of the multi-modal blood- based test reaches thresholds consistent with available stool-based screening options. • Analysis of the full cohort is ongoing, as is one-year clinical
Slide 11: Acknowledgements
Acknowledgements • Healthy individuals undergoing CRC screening who consented to this research • Study teams at HM Hospitales • Collaborators at Guardant Health ppeinado@hmhospitales.com @DDWMeeting | #DDW2022